RAPID MICRO BIOSYSTEMS, INC. (RPID) Financial Ratio Screen

NASDAQ Healthcare United States USD 100M
RATIOS FAIL*
Automated financial screen · activity assessed separately
RAPID MICRO BIOSYSTEMS, INC. (RPID) is potentially non-compliant in the automated ratio model. The company's debt ratio of 31.9% exceeds the 30% MSCI new-inclusion threshold relative to total assets. RAPID MICRO BIOSYSTEMS, INC. operates in the Healthcare sector.

Track RPID screening changes

Get an email when this stock's published screening status or underlying ratios change.

MSCI new-inclusion financial-ratio snapshot

RPID financial screening at a glance

RATIOS FAIL*Financial ratios shown separately from business review — not a fatwa
Debt ratio
31.9%
Fail vs 30%
Cash ratio
51.2%
Fail vs 30%
Receivables + cash
55.5%
Fail vs 30%
Impermissible income
11.3%
Fail vs 5%

Calculation date: 2026-09-01. Financial period used: December 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.

Independent method comparison

What the available screens say

How MSCI, FTSE and S&P-style screens differ
Request this stock review
MSCI-styleFinancial criteria not metAt least one available ratio exceeds its threshold
FTSE/Yasaar-styleFinancial criteria not metAt least one available ratio exceeds its threshold
S&P-style provisionalNot yet availableRequired denominator or financial data is incomplete
Business activityAssessment pendingFinancial results do not determine business permissibility
Complete screening result: not yet completeA complete result requires both supported financial criteria and adequate activity evidence. This site does not issue a fatwa or official index decision.
Financial periodDecember 2025Calculation date2026-09-01S&P-style historynot availableLast activity reviewnot yet reviewed

The request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.

Business activity evidence

Activity assessment in progress

The supplied classification (Medical Devices) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.

Revenue segments: Not yet checked against an SEC annual filing.

Profile description reviewed: Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switzerland, Germany, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the antiquated, manual microbial quality control (MQC), testing workflows for therapeutic modalities, such as biologics and cell and gene therapies, vaccines, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus Mold Alarm software; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings

A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.

Published-ratio reproductions (not certifications)

The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
MSCI 31.9%
/ 30%
51.2%
/ 30%
55.5%
/ 30%
11.28%
/ 5%
RATIOS FAIL*
FTSE 31.9%
/ 33%
51.2%
/ 33%
55.5%
/ 50%
11.28%
/ 5%
RATIOS FAIL*

Financial Highlights

EPS
$-1.00
P/B Ratio
2.9
EV/EBITDA
-1.9
EV: $85M
Revenue
$28M
Growth: 37.3%
Beta
1.4
High volatility
Current Ratio
3.3

Profitability

Gross Margin 3.1%
Operating Margin -108.2%
Net Margin -140.3%
Return on Equity (ROE) -86.8%
Return on Assets (ROA) -34.2%

Cash Flow & Balance Sheet

Operating Cash Flow-$44M
Free Cash Flow-$46M
Total Debt$24M
Debt-to-Equity71.9
Current Ratio3.3
Total Assets$75M

Price & Trading

Last Close$2.28
50-Day MA$3.79
200-Day MA$3.44
Avg Volume272K
Beta1.4
52-Week Range
$1.86
$4.94

Financial data provenance and verification

The displayed fields were imported from yfinance on 2026-03-29 for the financial period December 2025. This is a secondary data feed and can differ from amended or newly filed statements.

Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.

About RAPID MICRO BIOSYSTEMS, INC. (RPID)

CEO
Mr. Robert G. Spignesi Jr.
Employees
171
Sector
Healthcare
Industry
Medical Devices
Country
United States
Exchange
NASDAQ
Market Cap (listing currency)
USD 100M
Currency
USD

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switzerland, Germany, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the antiquated, manual microbial quality control (MQC), testing workflows for therapeutic modalities, such as biologics and cell and gene therapies, vaccines, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus Mold Alarm software; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Popular halal stock checks

Explore other frequently viewed automated stock screens and compare the available financial ratios.

Frequently Asked Questions

Is RAPID MICRO BIOSYSTEMS, INC. (RPID) halal to invest in?

The current automated result is Financial criteria not met or an activity exclusion was detected. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.

What is RAPID MICRO BIOSYSTEMS, INC.'s debt ratio?

RAPID MICRO BIOSYSTEMS, INC.'s debt ratio is 31.9% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.

What are RAPID MICRO BIOSYSTEMS, INC.'s key financial metrics?

RAPID MICRO BIOSYSTEMS, INC. has a market capitalization of USD 100M in its listing currency, and revenue of $28M. The company maintains a gross margin of 3.1% and a net margin of -140.3%. Return on equity stands at -86.8%.

How often is the screening data updated?

Calculation date: 2026-09-01. Financial period: December 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.